Pilocarpine

Pilocarpine

SCHEMBL3078492

CC[C@@H]1C(=O)OCC1Cc1cncn1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1CHRM3

The experimentally established mechanism targets of Pilocarpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 2/20 1.00
CHRM3 known ✓ P20309 2/20 1.00
LMNA P02545 3/20 1.00
CYP3A4 P08684 3/20 1.00
CHRM5 P08912 3/20 1.00
CHRM4 P08173 2/20 1.00
CYP2C9 P11712 2/20 1.00
CHRM2 P08172 1/20 1.00
CYP2A6 P11509 1/20 1.00
CNR1 P21554 1/20 1.00
HTR2A P28223 1/20 1.00
CYP2A13 Q16696 1/20 1.00
MEN1 O00255 1/20 1.00
USP2 O75604 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
ALOX15 P16050 1/20 1.00
ALOX12 P18054 1/20 1.00
NFKB1 P19838 1/20 1.00
MAPK1 P28482 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pilocarpine SCHEMBL188019 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL678045 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL9213198 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL15146 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL41890 1.00 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL725541 0.99 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL1670751 0.99 LMNA (0.97) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL5504377 0.99 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL7076217 0.99 LMNA (1.00) LMNACYP3A4CHRM5CHRM4CHRM1
Pilocarpine SCHEMBL4972337 0.99 LMNA (0.97) LMNACYP3A4CHRM5CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233941-A1 Co-Crystals of Calixarenes and Biologically Active Molecules CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2009-09-17 US claimed
CN-117567440-A Synthesis method of cholinergic receptor agonist 南京恒道医药科技股份有限公司 2024-02-20 CN disclosed
US-10933052-B2 Compositions and methods for the treatment of eye disorders CELLIX BIO PRIVATE LIMITED (IN) 2021-03-02 US disclosed
US-20200179343-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS CELLIX BIO PRIVATE LTD (IN) 2020-06-11 US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 US disclosed
US-20090233941-A1 Co-Crystals of Calixarenes and Biologically Active Molecules CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2009-09-17 US disclosed
US-20090209615-A1 INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-08-20 US disclosed
EP-0559700-B1 NOVEL PILOCARPINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION SANTEN OY (FI) 2000-04-26 EP disclosed
US-5436350-A Glaucoma treatment SANTEN PHARMACEUTICAL CO., LTD. (JP) 1995-07-25 US disclosed
EP-0642501-A1 NOVEL PILOCARPINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION LEIRAS OY (FI) 1995-03-15 EP disclosed
WO-1993024466-A1 NOVEL PILOCARPINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION LEIRAS OY (FI) 1993-12-09 WO disclosed
US-4977176-A Pilocarpine compounds which are used as pharmaceutical agents SANDOZ LTD. (CH) 1990-12-11 US disclosed
US-4835174-A Pilocarpine derivatives SANDOZ LTD. (CH) 1989-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233941-A1 Co-Crystals of Calixarenes and Biologically Active Molecules CALU, CALD1, CALR CHRM1 4051/4885CHRM3 2303/4885LMNA 1257/4885
US-20200179343-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS ALDH1A2, XDH, PDE6D CHRM1 1280/4885CHRM3 1409/4885LMNA 1111/4885
US-20090209615-A1 INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS MMP9, MMP10, MMP17 CHRM1 4049/4885CHRM3 3529/4885LMNA 1476/4885
US-10933052-B2 Compositions and methods for the treatment of eye disorders ALDH1A2, XDH, PDE6D CHRM1 1280/4885CHRM3 1409/4885LMNA 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.